Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A O'Rourke

Showing results (331-340 of 447) with videos related to

Pageof 45
Sort By:
The Oncologist|September 12, 2021
The Relationship Between Frailty and Emotional Health in Older Patients with Advanced CancerNikesha Gilmore, Lee Kehoe, Jessica Bauer, et al.
The Oncologist|July 26, 2021
Association Between Caregiver-Oncologist Discordance in Patient's Life Expectancy Estimates and Caregiver Perceived Autonomy Support by the OncologistGina Tuch, Chandrika Sanapala, Supriya G Mohile, et al.
American Heart Journal|June 20, 2006
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424William E Boden, Robert A O'rourke, Koon K Teo, et al.
Elife|December 2, 2024
Human airway macrophages are metabolically reprogrammed by IFN-γ resulting in glycolysis-dependent functional plasticityDonal J Cox, Sarah A Connolly, Cilian Ó Maoldomhnaigh, et al.
The American Journal of Cardiology|January 16, 2007
The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialWilliam E Boden, Robert A O'rourke, Koon K Teo, et al.
Clinical Colorectal Cancer|November 8, 2011
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancerLeonard Saltz, Suprith Badarinath, Shaker Dakhil, et al.
Cell|October 13, 2009
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesisCagla Eroglu, Nicola J Allen, Michael W Susman, et al.
Journal of the American College of Cardiology|February 14, 1998
Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research InvestigatorsD R Ferry, R A O'Rourke, A S Blaustein, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trialG B John Mancini, Eric R Bates, David J Maron, et al.
The New England Journal of Medicine|August 16, 2008
Effect of PCI on quality of life in patients with stable coronary diseaseWilliam S Weintraub, John A Spertus, Paul Kolm, et al.
Pageof 45

Showing results (331-340 of 447) with videos related to

Sort By:
Pageof 45
The Oncologist|September 12, 2021
The Relationship Between Frailty and Emotional Health in Older Patients with Advanced CancerNikesha Gilmore, Lee Kehoe, Jessica Bauer, et al.
The Oncologist|July 26, 2021
Association Between Caregiver-Oncologist Discordance in Patient's Life Expectancy Estimates and Caregiver Perceived Autonomy Support by the OncologistGina Tuch, Chandrika Sanapala, Supriya G Mohile, et al.
American Heart Journal|June 20, 2006
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424William E Boden, Robert A O'rourke, Koon K Teo, et al.
Elife|December 2, 2024
Human airway macrophages are metabolically reprogrammed by IFN-γ resulting in glycolysis-dependent functional plasticityDonal J Cox, Sarah A Connolly, Cilian Ó Maoldomhnaigh, et al.
The American Journal of Cardiology|January 16, 2007
The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialWilliam E Boden, Robert A O'rourke, Koon K Teo, et al.
Clinical Colorectal Cancer|November 8, 2011
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancerLeonard Saltz, Suprith Badarinath, Shaker Dakhil, et al.
Cell|October 13, 2009
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesisCagla Eroglu, Nicola J Allen, Michael W Susman, et al.
Journal of the American College of Cardiology|February 14, 1998
Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research InvestigatorsD R Ferry, R A O'Rourke, A S Blaustein, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trialG B John Mancini, Eric R Bates, David J Maron, et al.
The New England Journal of Medicine|August 16, 2008
Effect of PCI on quality of life in patients with stable coronary diseaseWilliam S Weintraub, John A Spertus, Paul Kolm, et al.
Pageof 45